Abstract
Interleukin-6 (IL-6) is a multifunctional cytokine which contributes to inflammation and tissue injury in several diseases. Thus, inhibition of IL-6 production may be a useful strategy for treatment of patients with diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). A synthetic nonpsychoactive cannabinoid, ajulemic acid (AjA), prevents joint damage in experimental arthritis. Results of experiments presented here indicate that addition of AjA (3-30 μM) to human monocyte derived macrophages in vitro reduces steady state levels of IL-6 mRNA and the subsequent secretion of IL-6 from LPS stimulated cells. Although AjA binds to and activates PPARγ, its anti IL-6 effects are PPARγ independent. These studies provide evidence to support the view that AjA may prove to be an effective, safe antiinflammatory agent.
Original language | English (US) |
---|---|
Pages (from-to) | 631-635 |
Number of pages | 5 |
Journal | Rheumatology International |
Volume | 28 |
Issue number | 7 |
DOIs | |
State | Published - May 2008 |
Externally published | Yes |
Keywords
- Cannabinoid acid
- Inflammation
- Interleukin-6
- Macrophages
- Rheumatoid arthritis
ASJC Scopus subject areas
- Rheumatology
- Immunology and Allergy
- Immunology